Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - azithromycin, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide; citric acid monohydrate - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 3000 iu - injection, solution - excipient ingredients: sodium chloride; water for injections - xyntha is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 2000 iu - injection, solution - excipient ingredients: water for injections; sodium chloride - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 1000 iu - injection, solution - excipient ingredients: sodium chloride; water for injections - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 500 iu - injection, solution - excipient ingredients: sodium chloride; water for injections - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 250 iu - injection, solution - excipient ingredients: water for injections; sodium chloride - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 2.103 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for the prevention of post-operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 1.051 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for the prevention of post-operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - amifostine, quantity: 500 mg - injection, powder for - excipient ingredients: - to decrease the incidence of neutropenia related fever and infection induced by dna-binding chemotherapeutic agents (classical alkylating agents such as cyclophosphamide and non-classical alkylating agents such as mitomycin-c and platinum-containing drugs); decrease in the incidence of acute and cumulative nephrotoxicity associated with platinum-based therapy; and the provision of better adherence to these types of chemotherapy regimens. indications as at 31 march 2000: ethyol is indicated to decrease the incidence of neutropenia-related fever and infection induced by dna-binding chemotherapeutic agents (classical alkylating agents such as cyclophosphamide and non-classical alkylating agents such as mitomycin-c and platinum containing drugs); decrease the incidence of acute and cumulative nephrotoxicity associated with platinum-based therapy; and to provide better adherence to these types of chemotherapy regimens. ethyol is also indicated to protect against acute and late xerostomia associated with standard fractionated radiation therapy in patients with head and neck cancer.